X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (518) 518
male (427) 427
prostatic neoplasms - drug therapy (244) 244
aged (237) 237
middle aged (232) 232
tosyl compounds - adverse effects (197) 197
tosyl compounds - therapeutic use (193) 193
anilides - therapeutic use (180) 180
tosyl compounds (175) 175
nitriles (159) 159
prostate cancer (159) 159
index medicus (158) 158
anilides - adverse effects (157) 157
androgen antagonists - therapeutic use (152) 152
urology & nephrology (145) 145
adult (132) 132
female (131) 131
androgen antagonists - adverse effects (128) 128
bicalutamide (108) 108
anilides - administration & dosage (107) 107
aged, 80 and over (104) 104
oncology (97) 97
prostatic neoplasms - pathology (97) 97
treatment outcome (95) 95
asthma - drug therapy (93) 93
tosyl compounds - administration & dosage (93) 93
nitriles - adverse effects (87) 87
nitriles - therapeutic use (87) 87
cancer (82) 82
care and treatment (77) 77
animals (72) 72
antineoplastic agents, hormonal - therapeutic use (70) 70
androgen antagonists - administration & dosage (69) 69
double-blind method (67) 67
carcinoma (66) 66
prostate-specific antigen - blood (66) 66
asthma (63) 63
nitriles - administration & dosage (63) 63
zafirlukast (62) 62
anti-asthmatic agents - therapeutic use (60) 60
leukotriene antagonists - therapeutic use (60) 60
tosyl compounds - pharmacology (60) 60
flutamide (59) 59
pharmacology & pharmacy (57) 57
therapy (57) 57
antineoplastic agents, hormonal - adverse effects (55) 55
follow-up studies (54) 54
radiotherapy (53) 53
quality of life (50) 50
prostatic neoplasms - blood (48) 48
antineoplastic agents - therapeutic use (47) 47
time factors (46) 46
adolescent (45) 45
allergy (45) 45
anti-asthmatic agents - adverse effects (45) 45
orchiectomy (44) 44
antineoplastic agents - adverse effects (43) 43
monotherapy (43) 43
prospective studies (43) 43
disease progression (42) 42
leukotriene antagonists - adverse effects (42) 42
drug therapy (41) 41
prostatic neoplasms - mortality (41) 41
radical prostatectomy (41) 41
men (40) 40
prostatic neoplasms - surgery (40) 40
research (40) 40
castration (39) 39
antineoplastic combined chemotherapy protocols - therapeutic use (38) 38
prostatic neoplasms - therapy (38) 38
adenocarcinoma - drug therapy (37) 37
combined modality therapy (36) 36
neoplasm staging (36) 36
administration, oral (34) 34
anilides - pharmacology (34) 34
immunology (34) 34
medicine, general & internal (34) 34
prostatic neoplasms - radiotherapy (34) 34
antineoplastic agents, hormonal - administration & dosage (33) 33
child (33) 33
medicine & public health (33) 33
flutamide - therapeutic use (32) 32
goserelin - administration & dosage (32) 32
androgens (31) 31
disease-free survival (31) 31
dose-response relationship, drug (31) 31
prostatectomy (31) 31
analysis (29) 29
androgen deprivation therapy (29) 29
drug administration schedule (29) 29
drug therapy, combination (29) 29
survival (29) 29
chemotherapy, adjuvant (28) 28
follow-up (28) 28
goserelin - therapeutic use (28) 28
prostate (28) 28
antineoplastic agents - administration & dosage (27) 27
montelukast (27) 27
trial (27) 27
gonadotropin-releasing hormone - agonists (26) 26
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (530) 530
Japanese (7) 7
Spanish (7) 7
French (5) 5
Italian (5) 5
German (4) 4
Russian (2) 2
Afrikaans (1) 1
Finnish (1) 1
Hebrew (1) 1
Hungarian (1) 1
Polish (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Cancer Research, ISSN 1078-0432, 10/2013, Volume 19, Issue 19, pp. 5505 - 5512
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 02/2017, Volume 376, Issue 5, pp. 417 - 428
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2009, Volume 360, Issue 24, pp. 2516 - 2527
A current standard treatment for locally advanced prostate cancer is external-beam radiotherapy combined with 3 years of androgen suppression. Adverse events,... 
PHASE-III TRIAL | DEPRIVATION THERAPY | IRRADIATION | MEDICINE, GENERAL & INTERNAL | MANAGEMENT | EORTC | RANDOMIZED-TRIAL | QUALITY-OF-LIFE | RADIOTHERAPY | RADIATION-THERAPY | ADJUVANT | Anilides - therapeutic use | Prostatic Neoplasms - radiotherapy | Follow-Up Studies | Anilides - adverse effects | Humans | Middle Aged | Male | Gonadotropin-Releasing Hormone - analogs & derivatives | Flutamide - adverse effects | Treatment Failure | Aged, 80 and over | Adult | Flutamide - therapeutic use | Prostatic Neoplasms - drug therapy | Drug Administration Schedule | Proportional Hazards Models | Combined Modality Therapy | Prostatic Neoplasms - mortality | Disease-Free Survival | Tosyl Compounds - adverse effects | Heart Diseases - mortality | Tosyl Compounds - therapeutic use | Quality of Life | Radiotherapy, Conformal - adverse effects | Aged | Androgen Antagonists - administration & dosage | Androgen Antagonists - adverse effects | Nitriles - adverse effects | Nitriles - therapeutic use | Heart attacks | Medical treatment | Mortality | Radiation therapy | Prostate cancer | Cancer therapies | Quality of life | Index Medicus | Abridged Index Medicus | Androgen Antagonists | Anilides | Life Sciences | Prostatic Neoplasms | Flutamide | Heart Diseases | Radiotherapy, Conformal | Gonadotropin-Releasing Hormone | Nitriles | Tosyl Compounds | Cancer
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2013, Volume 368, Issue 14, pp. 1314 - 1325
Despite theoretical benefits of intermittent as compared with continuous androgen-deprivation therapy in patients with metastatic prostate cancer, intermittent... 
MEDICINE, GENERAL & INTERNAL | THERAPY | CLINICAL-TRIAL | FLUTAMIDE | QUALITY-OF-LIFE | SUPPRESSION | CARCINOMA | LEUPROLIDE | Confidence Intervals | Follow-Up Studies | Anilides - adverse effects | Humans | Middle Aged | Male | Gonadotropin-Releasing Hormone - analogs & derivatives | Nitriles - administration & dosage | Antineoplastic Agents, Hormonal - adverse effects | Neoplasm Metastasis - drug therapy | Penile Erection - drug effects | Gonadotropin-Releasing Hormone - therapeutic use | Goserelin - adverse effects | Prostatic Neoplasms - drug therapy | Goserelin - administration & dosage | Prostatic Neoplasms - pathology | Tosyl Compounds - administration & dosage | Drug Administration Schedule | Antineoplastic Agents, Hormonal - administration & dosage | Prostate-Specific Antigen - blood | Prostatic Neoplasms - mortality | Tosyl Compounds - adverse effects | Anilides - administration & dosage | Survival Analysis | Quality of Life | Aged | Androgen Antagonists - administration & dosage | Nitriles - adverse effects | Usage | Care and treatment | Patient outcomes | Androgen suppression therapy | Drug therapy | Prostate cancer | Methods | Cancer | Statistical analysis | Mental disorders | Prostate-specific antigen | Clinical trials | Patients | Survival | Quality of life | Metastases | Androgens | Castration | Stem cells | Luteinizing hormone | Prostate
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2015, Volume 33, Issue 4, pp. 332 - 339
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 2, pp. 153 - 163
Journal Article
The Cochrane database of systematic reviews, ISSN 1469-493X, 2014, Volume 6, Issue 6, p. CD009266
Journal Article
Journal Article
BJU International, ISSN 1464-4096, 12/2012, Volume 110, Issue 11, pp. 1729 - 1735
Journal Article
Cancer, ISSN 0008-543X, 08/2016, Volume 122, Issue 16, pp. 2595 - 2603
Journal Article